Discussion on hADM safety…traceability tracking from the donation phase

A US tissue bank expert presented the full project lifecycle management system of hADM

Highlighted the guidelines of donor consent, infectious disease screening, sterilization, and quality review

"Tissues are supplied to patients only after passing a rigorous monitoring system"

The Symposium of the Korean Society for Anti-Aging Dermatology

Amid growing interest in human-derived extracellular matrix (ECM), the industry is also focusing on its safety profile. Currently, ECM is reported to be properly regulated through rigorous validation protocols.

Human acellular dermal matrix (hADM) used in aesthetic and reconstructive fields is supplied to patients through a strict full project lifecycle management system that spans from donor consent and infectious disease screening to processing, sterilization, quality review, and traceability tracking.

At the 16th Summer Symposium of the Korean Society for Anti-Aging Dermatology held on June 28, Faith P. Case, a tissue bank expert, introduced the ethical standards, regulatory compliance, and safety validation frameworks of US tissue banks during a session titled 'hADM, The center of the ECM era, Their similar yet different stories.'

Case is an American Society for Quality (ASQ) Certified Quality Manager and an American Association of Tissue Banks (AATB) Certified Tissue Bank Specialist, currently serving as the Vice Chair of the AATB Accreditation Committee. She also has extensive experience conducting inspections and audits for the US Food and Drug Administration (FDA) and the South Korean Ministry of Food and Drug Safety (MFDS).

The hADM safety management system initiates from donor consent

Case emphasized that human-derived tissue allografts, such as hADM, fundamentally differ from synthetic biomaterials from their very origins. She noted that a donor's decision precedes the manufacturing process, serving as the critical first step in safety management.

Faith P. Case, a tissue bank expert

​"Human tissue does not originate in a laborator. It begins with a human decision to donate," she stated. "This decision leads to a moral responsibility to manage the donation process with absolute transparency."

The ethical foundation of the US tissue banking system is the Uniform Anatomical Gift Act (UAGA). This legislation serves as the legal bedrock for voluntary tissue donation and informed consent protocols. Donors or their families provide explicit authorization for which specific tissues may be recovered and the exact clinical fields, such as reconstructive or aesthetic purposes, in which they may be used.

Case explained, "Securing high-caliber tissue and maintaining rigorous safety standards is not merely a regulatory compliance, but a pledge to honor the donor's intent," and added, "When public trust is protected, the continuity of sustainable therapeutics for patients is guaranteed."

Case further explained the structurally integrated relationship between donor consent and FDA regulations. While the donor's authorization serves as the trigger for tissue recovery, FDA regulations provide the mechanism to validate whether the recovered tissue meets the standards required for patient administration.

​"Donation is merely the starting point. It does not automatically guarantee the production of an allograft," Case said. "If a donor fails to pass the initial safety screening protocols, the process stops at that stage, and no tissue is recovered."

Only validated tissues reach patients following infectious disease screening and aseptic recovery

Following recovery, the timeline proceeds through infectious disease screening, aseptic recovery, and validated processing and sterilization.

According to Case, US tissue banks review donors' medical and behavioral histories and use Nucleic Acid Amplification Testing (NAT) to minimize the risk of acute asymptomatic infections. The screening panel comprehensively covers HIV, Hepatitis B, Hepatitis C, Syphilis, HTLV, and West Nile Virus, among others.

Case highlighted that the regulatory directions of the US FDA and the Korean MFDS converge on the singular goal of patient protection.

​"While the FDA and the MFDS may vary in procedural and administrative actions, their ultimate destination is identical, which is absolute patient protection," Case said. "The core safety values demanded in donor screening and infectious disease testing remain fundamentally aligned."

Regarding safety validation, operational environmental control was proposed as a key factor. Case stressed that "Microorganisms do not read documentation. They react to the environment. Tissue safety validation must function as a multi-layered defense system that actively mitigates contamination risks across every single phase of the tissue lifecycle."

Contamination risks are strictly controlled from the recovery phase onward, after which processing eligibility is determined through formal evaluations by physicians and the tissue bank's medical director. The processing phase operates under a strict protocol in which only one donor's tissue is processed in a designated zone at any given time, supported by cleanroom environments, HEPA filtration, validated sterilization protocols, and cold-chain management.

Finished products are never distributed immediately. A dedicated quality professional must independently review the medical director's release determination, donor testing records, processing logs, and sterilization data before the tissue can finally advance to the patient administration phase.

Completing safety validation via unique ID-based traceability systems

Case detailed traceability as another core benchmark that substantiates hADM safety.

Every donor is assigned a unique identification number, which remains seamlessly linked from tissue recovery through processing, storage, international logistics, and final clinical administration at the point of care. This system ensures that if an adverse event or issue arises, the system can trace the lineage back to the initial donation phase or pinpoint exactly which patient received a specific tissue unit.

Case mentioned, "The true sophistication of modern allografts does not lie merely within the clinical application itself, but within the invisible safety nets that ensure patient safety." 

"Tissue banking is ultimately about honoring the gift of donation and protecting the patients who receive it," Case added. "This responsibility is sustained through error-proof operating systems and precise accountability frameworks."

Concluding the session, the chairperson tied the lecture's implications directly to the broader discussion on ECM safety. The chair evaluated, "This lecture provided a clear, scientific evidence-based understanding of the ethical considerations and safety concerns previously raised by some regarding ECMs, based on validated international management and regulatory standards."